KRAS and lung cancer: Consistent with the anti-proliferative effect of NASTRp in NCI-H1734 cells, as shown in Fig 2A, NASTRp dramatically suppressed cell proliferation in all of the lung cancer cell lines with KRAS mutations we tested (IC50 = A549, 3.574 μM; NCI-H1792, 11.769 μM; NCI-H441, 11.074 μM; NCI-H1734, 4.025 μM).